Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An open-label study to investigate the safety and pharmacokinetics of multiple ascending doses of antisense oligonucleotide STK-001 in children and adolescents with Dravet syndrome

Next Previous
X
Search
Trial Profile

An open-label study to investigate the safety and pharmacokinetics of multiple ascending doses of antisense oligonucleotide STK-001 in children and adolescents with Dravet syndrome

Status: Completed
Phase of Trial: Phase I/II

Latest Information Update: 12 Sep 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Zorevunersen (Primary)
  • Indications Dravet syndrome
  • Focus Adverse reactions; Pharmacokinetics
  • Acronyms ADMIRAL; STK-001-DS-102 (ADMIRAL)
  • Sponsors Stoke Therapeutics

    • Most Recent Events

    • 10 Sep 2024 Results published in a Stoke Therapeutics media release
    • 10 Sep 2024 According to a Stoke Therapeutics media release, new data from this trial presented at presentations at the 15th European Epilepsy Congress (EEC) for Dravet syndrome.
    • 03 Sep 2024 According to a Stoke Therapeutics media release, data from the study will be presented at the 15th European Epilepsy Congress (EEC) taking place September 7 - 11, in Rome, Italy.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top